Evaluating the impact of GLP-1 receptor agonists in combination with total neoadjuvant therapy for locally advanced rectal cancer - PubMed
12 hours ago
- #Neoadjuvant therapy
- #GLP-1 agonists
- #Rectal cancer
- Total neoadjuvant therapy (TNT) is a standard treatment for rectal cancer, improving pathological complete response and long-term survival.
- GLP-1 receptor agonists (GLP-1 RAs) offer benefits in weight loss, metabolic regulation, and anti-inflammatory effects, with potential anticancer properties.
- This review explores the biological basis and therapeutic benefits of combining GLP-1 RAs with TNT for locally advanced rectal cancer.
- GLP-1 RAs may influence tumor biology and treatment tolerance by affecting visceral fat, insulin resistance, and systemic inflammation.
- Preclinical and clinical data suggest GLP-1-induced metabolic changes could enhance chemotherapy effectiveness and improve surgical and oncological outcomes.
- Integrating GLP-1 RAs into rectal cancer treatment is a promising area for further research, especially in metabolically vulnerable populations.